安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab . . .
Anonymous board for Novartis
- Novartis | Cafepharma
Swiss pharmaceutical giant Novartis has officially begun construction on a new global biomedical research center in San Diego, California, marking a major expansion of its US research footprint The state-of-the-art facility, part of a broader $23 billion investment in US R D and manufacturing, will span roughly 466,000 square feet and is designed to support end-to-end drug discovery across
- Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
March 20 2026 - Novartis buys breast cancer drug for $2b to keep up with myriad rivals Biopharma headlines today span acquisitions, recalls and regulatory moves, with obesity drugs, global competition and supply challenges continuing to shape the industry’s direction Novartis buys breast cancer drug for $2b to keep up with myriad rivals
- Novartis terminating midphase SMURF1 trial | Cafepharma
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication
- October 27 2025 - Novartis shares slip, Avidity soars after $12 billion . . .
Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly board, Novo Nordisk boardMapLight goes public via $250M IPO to fund Cobenfy competitor
- Novartis plots 58 layoffs in N. J. amid ongoing efficiency drive . . .
More than three years after launching a new corporate structure, Novartis is still making changes to its organization In the latest move to streamline its business, Novartis will lay off 58 employees who report to the drugmaker’s U S headquarters in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) notice (PDF)
- February 9 2026 - Lilly buys Orna in $2. 4B deal to enter in vivo CAR-T . . .
Lilly buys Orna in $2 4B deal to enter in vivo CAR-T arena Eli Lilly board Takeda, Iambic partner in latest pharma AI push Takeda board Novartis starts construction on new research facility in San Diego Novartis board Becton Dickinson slides despite Q1 beat as full-year outlook disappoints Becton Dickinson board *please scroll down for all the
- Xoma | Cafepharma
Novartis is discontinuing the development of the anti-TGFβ antibody NIS793 and is returning it to Xoma Corporation, according to an SEC filing posted Friday Following the discontinuation, Novartis will stop enrollment into all active clinical studies of NIS793 but will still collect data once these studies have concluded
|
|
|